Cipla’s wholly owned subsidiary — Goldencross Pharma has completed the closing of Wellthy Therapeutics, transaction representing an acquisition of 11.71% stake in Wellthy on fully diluted basis on March 08, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.